A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder

详细信息    查看全文

• 作者：Danielle S. Cha^a ; ^b ; Michael W. Best^c ; Christopher R. Bowie^d ; ^e ; Laura Ashley Gallaugher^a ; Hanna O. Woldeyohannes^a ; Joanna K. Soczynska^a ; ^b ; Gary Lewis^f ; Glenda MacQueen^g ; Barbara J. Sahakian^h ; Sidney H. Kennedy^a ; ^b ; Jane P. Luiⁱ ; Rodrigo B. Mansur^j ; Roger S. McIntyre^a ; ^b ; ^{roger.mcintyre@uhn.on.ca}
• 关键词：Major depressive disorder ; Intranasal insulin ; Cognition ; Cognitive ; Cognitive impairment ; Cognitive dysfunction ; Emotional processing
• 刊名：Journal of Affective Disorders
• 出版年：2017
• 出版时间：1 March 2017
• 年：2017
• 卷：210
• 期：Complete
• 页码：57-65
• 全文大小：519 K
• 卷排序：210

文摘

Intranasal insulin did not significantly improve depressive symptomatology compared to placebo. Notwithstanding results, intranasal insulin may offer benefits in domain-based psychopathology. Improvements in stratification strategies are necessary to identify responsive subpopulations.